EUVIMEDEUVIMED entdecken
Crossref

The Therapeutic Potential of (+)-Afzelechin for Alleviating Sepsis-Associated Pulmonary Injury

Sanghee Cho, Yun Jin Park, Eunjeong Kim, Jong-Sup Bae

Journal of Medicinal Food · 2024

DOI: 10.1089/jmf.2023.k.0228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Food, 2024. Verfasst von Sanghee Cho und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Korea. Hauptthemen laut MEDLINE: Acute Lung Injury, Sepsis, Flavonoids, Phenols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sepsis-induced acute lung injury (ALI) poses a common and formidable challenge in clinical practice, currently lacking efficacious therapeutic approaches. This study delves into the evaluation of (+)-afzelechin (AZC), a natural compound derived from Bergenia ligulata with a diverse array of properties, encompassing antioxidant, anticancer, antimicrobial, and cardiovascular effects to ascertain its effectiveness and underlying mechanisms in mitigating sepsis-induced ALI through animal experimentation. An ALI mouse model induced by sepsis was established through lipopolysaccharide (LPS) administration, and various analytical techniques, including quantitative real-time polymerase chain reaction, Western blotting, and enzyme-linked immunosorbent assay were employed to gauge inflammatory cytokine levels, lung injury, and associated signaling pathways. The animal experiments revealed that AZC offered safeguards against lung injury induced by LPS while reducing inflammatory cytokine levels in both blood serum and lung tissue. Western blotting experiments revealed AZC's downregulation of the toll-like receptor (TLR)4/NF-κB pathway and the upregulation of PI3K/Akt, coupled with inhibition of the Hippo and Rho signaling pathways. These findings underscore AZC's efficacy in ameliorating sepsis-induced ALI by modulating cytokine storms and curtailing inflammation via the regulation of TLR4/NF-κB, PI3K/Akt, Hippo, and Rho signaling pathways. This work serves as a foundation for additional exploration into AZC's mechanisms and its potential as a therapy for sepsis-induced ALI. Animals in accordance with Kyungpook National University (IRB No. KNU 2022-174).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Lung InjurySepsisFlavonoidsPhenolsHumansMiceAnimalsNF-kappa BProto-Oncogene Proteins c-aktLipopolysaccharidesPhosphatidylinositol 3-KinasesLungCytokines

Stichwörter der Autor:innen

(+)-afzelechinHippoRhoacute lung injurysepsis

Substanzen

NF-kappa BafzelechinProto-Oncogene Proteins c-aktLipopolysaccharidesPhosphatidylinositol 3-KinasesCytokinesFlavonoidsPhenols

Autor:innen und Institutionen

  • College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Korea.
  • Department of Biology, College of Natural Sciences, Kyungpook National University, Daegu, Korea.

Zitieren

APA

Cho, S., Park, Y. J., Kim, E., & Bae, J. S. (2024). The Therapeutic Potential of (+)-Afzelechin for Alleviating Sepsis-Associated Pulmonary Injury. Journal of Medicinal Food. https://doi.org/10.1089/jmf.2023.k.0228

Vancouver

Cho S, Park YJ, Kim E, Bae JS. The Therapeutic Potential of (+)-Afzelechin for Alleviating Sepsis-Associated Pulmonary Injury. Journal of Medicinal Food. 2024. doi:10.1089/jmf.2023.k.0228

BibTeX
@article{Cho2024,
  author = {Cho, Sanghee and Park, Yun Jin and Kim, Eunjeong and Bae, Jong-Sup},
  title = {The Therapeutic Potential of (+)-Afzelechin for Alleviating Sepsis-Associated Pulmonary Injury},
  journal = {Journal of Medicinal Food},
  year = {2024},
  doi = {10.1089/jmf.2023.k.0228}
}
Kostenlos starten →